All Stories

  1. Anticancer Properties of Antipsychotic Drugs
  2. Stratification in Immunopsychiatry
  3. Effects of Antipsychotics on Bone Mineral Density in Schizophrenia
  4. Diabetes mellitus type 2 as an underlying, comorbid or consequent state of mental disorders
  5. Neuroimmune, clinical and treatment challenges in multiple sclerosis-related psychoses
  6. Targeting Underlying Inflammation in Carcinoma Is Essential for the Resolution of Depressiveness
  7. Prescription of selective serotonin reuptake inhibitors in COVID-19 infection needs caution
  8. Galectin-3 mediated risk of inflammation in stable schizophrenia, with only possible secondary consequences for cognition
  9. Galectin-3 Involvement in Cognitive Processes for New Therapeutic Considerations
  10. The Influence of Serum Uric Acid on the Brain and Cognitive Dysfunction
  11. Uric Acid Potential Role in Systemic Inflammation and Negative Symptoms After Acute Antipsychotic Treatment in Schizophrenia
  12. Autoimmunity and psychosis
  13. Breast cancer in schizophrenia could be interleukin-33-mediated
  14. Galectin-3 possible involvement in antipsychotic-induced metabolic changes of schizophrenia: A minireview
  15. Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity
  16. Psychiatry Trainees' Attitudes, Knowledge, and Training in Addiction Psychiatry—A European Survey
  17. Chlorpromazine as a Potential Antipsychotic Choice in COVID-19 Treatment
  18. Type 17 Immune Response Facilitates Progression of Inflammation and Correlates with Cognition in Stable Schizophrenia
  19. Peripheral Markers of Immune Response in Major Psychiatric Disorders: Where Are We Now and Where Do We Want to Be?
  20. The use of complementary serological and molecular testing for blood-borne pathogens and evaluation of socio-demographic characteristics of intravenous drug users on substitution therapy from Sumadia district of Serbia
  21. Oxidative stress and neuroinflammation should be both considered in the occurrence of fatigue and depression in multiple sclerosis
  22. IL-33/ST2 Pathway and Galectin-3 as a New Analytes in Pathogenesis and Cardiometabolic Risk Evaluation in Psychosis
  23. Interplay of Brain-Derived Neurotrophic Factor and Cytokines in Schizophrenia
  24. POSITIVE IMPACT OF PRESCRIBED PHYSICAL ACTIVITY ON SYMPTOMS OF SCHIZOPHRENIA: RANDOMIZED CLINICAL TRIAL
  25. Interleukin-6 in Schizophrenia—Is There a Therapeutic Relevance?
  26. Cross-national Trainee Collaboration-The EFPT Research Experience in Psychiatry
  27. Elevated sera levels of galectin-3 in stable schizophrenia
  28. The EFPT-PSUD survey
  29. Quality of Life in Primary Insomnia: Three-week Treatment With Zolpidem Vs. Lorazepam
  30. In vivo methodology in behavioural pharmacology - where are we now?
  31. Possible Role of TGF – B Pathways in Schizophrenia / Moguća Uloga TTGF - B Signalnih Puteva U Shizofreniji
  32. Cannabis as a Possible Treatment for Spasticity in Multiple Sclerosis / Kanabis Kao Moguci Tretman U Lecenju Spasticnosti Kod Multiple Skleroze
  33. Depression correlates with sexual dysfunction and fatigue in multiple sclerosis patients
  34. Increase systemic levels of IL-23 as a possible constitutive marker in schizophrenia
  35. The effect of antipsychotic drugs on nonspecific inflammation markers in the first episode of schizophrenia
  36. P.8.b.006 Side effects of zolpidem and temazepam in treating primary insomnia
  37. Antipsychotics can modulate the cytokine profile in schizophrenia: Attenuation of the type-2 inflammatory response
  38. 2030 – Can TGF- β be a valuable marker for psychosis?
  39. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse
  40. Pharmacotherapeutical possibilities in mental disorders: Current status in Serbia
  41. P.5.c.001 Memantine improves poststroke cognitive impairment supported with mirtazapine
  42. PO18-WE-62 Seizures as predictive parameter in outcome of delirium tremens
  43. P.l.c.056 The most frequent used drugs at psychiatric clinical centre Kragujevac in 2007